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Abstract
Background: An explosive global spreading of multidrug resistant Mycobacterium tuberculosis
(Mtb) is a catastrophe, which demands an urgent need to design or develop novel/potent
antitubercular agents. The Lysine/DAP biosynthetic pathway is a promising target due its specific
role in cell wall and amino acid biosynthesis. Here, we report identification of potential
antitubercular candidates targeting Mtb dihydrodipicolinate synthase (DHDPS) enzyme of the
pathway using virtual screening protocols.
Results: In the present study, we generated three sets of drug-like molecules in order to screen
potential inhibitors against Mtb drug target DHDPS. The first set of compounds was a
combinatorial library, which comprised analogues of pyruvate (substrate of DHDPS). The second
set of compounds consisted of pyruvate-like molecules i.e. structurally similar to pyruvate,
obtained using 3D flexible similarity search against NCI and PubChem database. The third set
constituted 3847 anti-infective molecules obtained from PubChem. These compounds were
subjected to Lipinski’s rule of drug-like five filters. Finally, three sets of drug-like compounds i.e.
4088 pyruvate analogues, 2640 pyruvate-like molecules and 1750 anti-infective molecules were
docked at the active site of Mtb DHDPS (PDB code: 1XXX used in the molecular docking
calculations) to select inhibitors establishing favorable interactions.
Conclusion: The above-mentioned virtual screening procedures helped in the identification of
several potent candidates that possess inhibitory activity against Mtb DHDPS. Therefore, these
novel scaffolds/candidates which could have the potential to inhibit Mtb DHDPS enzyme would
represent promising starting points as lead compounds and certainly aid the experimental designing
of antituberculars in lesser time.
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Causing massacre especially in Asia and Africa, Tubercu-
losis (TB) prevalence and mortality rates have probably
been mounting globally for last several years [1]. Further,
a s s o c i a t i o no fT Bw i t hH I Vp a t i e n t sa n de m e r g e n c eo f
multiple drug-resistant Mycobacterium tuberculosis (Mtb)
to isoniazid and rifampicin and extensive drug-resistant
Mtb to any floroquinolone, amikacin and capreomycin is
a growing alarm. Despondently, more than two million
people happen to be victim of TB annually and globally
[2-4]. World Health Organization (WHO) 2008 report
has mentioned the statistics regarding the occurrence of
9.2 million new cases and 1.7 million deaths from TB in
2006, out of which 0.7 million cases and 0.2 million
deaths were in HIV-positive patients [5]. These numbers
observed to be boosted compared with those reported by
the WHO for the previous years. Therefore, discovery of
novel unexploited drug target enzymes and their
inhibitors besides generating analogues of existing
drugs is a major challenge in the field of drug discovery
and designing.
The amino acids play a major role in defining the cellular
growth, cell wall and protein synthesis of bacterial
system. Importantly, the absence of de novo synthesis of
protein building blocks and requirement of amino acids
as dietary components in mammals implies that specific
inhibitors of amino acid biosynthetic pathways would
display a novel class of antibacterial agents through
inhibition of cell wall and protein synthesis with no
mammalian toxicity. For past few years, Lysine/DAP
biosynthetic pathway has been gaining high attention
due to its foremost feature in the synthesis of D, L-
diaminopimelic acid (meso-DAP) and lysine. Both
components are essential for cross-linking peptidoglycan
chains to provide strength and rigidity to the bacterial
cell wall [6-8]. It has been observed that Mycobacterium
cell walls are characterized by an unusual high DAP
content. Moreover, gene-knockout experiments with
Mycobacterium smegmatis has demonstrated the essenti-
ality of DAP pathway for the bacteria, where the absence
of DAP results in cell lysis and death [9]. In view of its
importance, the designing of potential inhibitors against
any enzyme of this pathway may display a novel classes
of antitubercular agents.
The present study mainly focused on dihydrodipicoli-
nate synthase (DHDPS) enzyme of the pathway,
catalyses the first committed step towards meso-DAP
formation by condensation of substrate pyruvate with
active site residue (LYS-171), which results in the
formation of a Schiff-base [10,11]. Next, tautomerisation
and aldol type reaction with aspartate b-semialdehyde
generates an enzyme-tethered acyclic intermediate that
undergoes transimination to form heterocyclic [(4S)-4-
hydroxy-2,3,4,5-tetrahydro-(2S)-dipicolinate] (HTPA).
The release of HTPA from the active site with elimination
of water molecules provides product dihydrodipicolinate
(DHDP) [12]. The three-dimensional crystal structures of
DHDPS from Escherichia coli, Nicotiana sylvestris, Staphy-
lococcus aureus, Mtb, Salmonella typhimurium, Bacillus
anthracis, Clostridium botulinum, Corynebacterium glutami-
cum, Thermotoga maritime and Bacillus clausii are available
at PDB database. Previously, various structural studies
have reported the conservation of active site residues
from different bacterial species [13-21].
Till date, designing of inhibitors against DHDPS (mainly
from E. coli) is being carried out using experimental
procedure; however, no potent inhibitors have been
reported. However, analogues of pyruvate such as a-
ketobutyrate, a-ketoglutarate, glyoxylate and fluoropyr-
uvate have been shown to be competitive inhibitors of
DHDPS with respect to pyruvate. Additionally, few
inhibitors based on DHDP or HTPA structures showing
weak to moderate inhibitory activity is also reported
[22-24]. Recently, Mitsakos et al [25] has demonstrated
that several experimentally known inhibitors displayed a
clear differentiation in inhibition of DHDPS enzymes
from different bacterial species, hence, suggested that
designing of inhibitors against DHDPS should be
specific to bacterial species rather than a broad-spectrum
inhibitor.
Keeping in view, the importance of DAP pathway in Mtb
and low outcome of DHDPS inhibitors using experi-
mental procedures, we have made an attempt to screen
inhibitors of Mtb DHDPS using virtual screening
procedures. The present work of screening of DHDPS
inhibitors is reported for the first time, hence, would be a
great help in aiding the experimental studies and
rational development of novel drugs against Mtb.
Methods
Generation of combinatorial library
of pyruvate analogues
The LeadGrow module of VLifeMDS [26] provides
facility for the generation of combinatorial library
starting with a template structure (also called as core/
scaffold) to which the side chains are attached/substi-
tuted from the list of given substituents. Thus, if X1 and
X2 are two substitution sites on the template, where X1
has L and X2 has M choices for the attachment/
substitution of atoms/groups, then a library with L × M
number of compounds can be generated. In the present
study, the substrate pyruvate was used as a template for
the library generation and three substitution sites namely
X1, X2, X3 were chosen as shown in Figure 1, where the
atoms/groups can be substituted. For X1 site, the
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as N, O, F, P, S, Cl, Br, I, whereas for X2 and X3 the alkyl
(ethyl, isopropyl, butyl, isobutyl, tertiary butyl, methyl),
alkene (vinyl, allyl), acids (carboxyl, carbonic), ketone
(methylketone), carbomethoxy (acetate, carbomethoxy),
charged (carboxylate), and others (amine, carbonyl,
-O-CH3,- O C 2H5,a m i d e ,c y n i d e ,c y n a t e ,i s o c y n a t e ,
-C = N, -N = C, azo, hydrazo, nitroso, nitro, sulfone,
- S=O O O ,o x i m e ,C H 2-C = N) subsitutions were
applied. The generated combinatorial library was sub-
jected to Lipinski’s rule of five filters [27] to get drug-like
orally-bioavailable compounds. Finally, we were left
with 4088 pyruvate analogues to be docked for the
screening of potential inhibitors against DHDPS.
Pyruvate-like molecules
Since the similarities in structures are indicative of
similarities in bioactivities, therefore, structure based
searching of databases/libraries has been gaining high
demand nowadays [28,29]. In the present study,
VLifeMDS package was used for carrying out 3D flexible
search (using pyruvate as a template) against most
popular databases i.e. National cancer Institute (NCI)
Open database with ~2,60,071 compounds, and a
library of sub/superstructures of pyruvate from Pub-
Chem database which constituted 21,061 compounds.
These databases were first subjected to Lipinski’s rule of
five constraints (mentioned earlier), which reduced their
size to ~160,000 and 17,157 compounds respectively.
The searching was based on 3D superimposition, where
the query pyruvate and the compounds present in the
databases were structurally superimposed for rmsd
calculations, in order to check whether the atoms in
the match mapping meets the spatial constrains (dis-
tance, angle, dihedral) in a query or not.
The databases generally store only a single low-energy
conformation or a limited number of conformations for
each compound, which may lead to the reduction in the
hit rates. Therefore to make the search more effective, the
3D flexible search was carried out in the present study.
Here, the conformers for each compound was generated
using Metropolis Monte Carlo simulations, which
explores the compound’s conformational search space
using random moves by altering torsion angle values.
Here, the tolerance limit (which defines the rmsd cut-
off) was set to 50%, such that the hits with rmsd value
greater than 50% were discarded. Following the 3D
search, 291 and 2349 compounds from NCI and
PubChem libraries were retrieved. Finally, we got total
2640 molecules, which are structurally similar to
pyruvate molecules. In this study, these molecules will
be called pyruvate-like molecules.
Anti-infective molecules
Additionally, 3847 anti-infective compounds, consisting
of 1743 antibacterials were retrieved from PubChem
database. Out of 3847, only 1750 anti-infectives satisfied
the Lipinski’s rule of five constraints. These compounds
were highly diverse from the pyruvate such that none of
the anti-infectives showed 2D/3D similarity with pyr-
uvate. Hence, the docking of these compounds would
help to screen the diverse classes of antitubercular agents
against Mtb DHDPS.
Ligand-receptor flexible docking
To find the binding affinities between target receptor and
screened out compounds, an automated flexible docking
of ligands at the flexible active site of receptor was
carried out using AutoDock (v.4.0) software [30]. The
software facilitates the internal degree of freedom along
with the values of translation and rotation for the side
chains of selected active residues as well as for the
ligands in search of its suitable bound conformations.
Undoubtedly, introduction of flexibility makes the
docking process computationally more expensive but
more superior than rigid ligand-receptor docking. Before
docking process, several separate pre-docking steps:
ligand preparation, receptor preparation and grid map
calculations were performed. The ligand and receptor
preparation stage involved the addition of hydrogen
atoms, computing charges, merging non-polar hydrogen
Figure 1
Pyruvate template with three substitution sites used
for the combinatorial library generation.
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conformed to the AutoDock atom types. Next, informa-
tion about rotatable torsion bonds that defines the bond
flexibility was acquired. The ligands and receptor
molecule preparation was followed by grid construction
using AutoGrid module. During grid construction, atom
types of the ligand, which acted as probes in the
calculation of grid maps, were identified. The grid with
default volume of 40 × 40 × 40 Å with a spacing of 0.375
Å centered on the receptor was prepared. For conforma-
tional search, the docking calculations using the genetic
algorithm (GA) procedure with default parameters was
performed. The GA computed the fitness of a docked
candidate every time by measuring the minimum values
of free energy binding (ΔG) based on different types of
energy evaluations. In the present study, the python
scripts were used for carrying out automated docking
process.
Results and discussion
In the present study, different virtual screening
approaches were used for selecting potential inhibitors
against Mtb DHDPS. The first approach employed the
generation of combinatorial library i.e. analogues of
pyruvate. In the second approach pyruvate-like mole-
cules generated using 3D flexible similarity search
against available databases/libraries. Thirdly, to screen
diverse classes of antitubercular agents, drug-like 1750
anti-infectives available at PubChem database were
retrieved. Finally, these three sets of compounds i.e.
generated pyruvate analogues, pyruvate-like molecules
and anti-infectives were docked into the active site of
receptor with the purpose of sorting potential inhibitors
of Mtb DHDPS.
The three-dimensional crystal structure of Mtb DHDPS
stored in the PDB file (code: 1XXX) [20] was obtained
from protein databank. Mtb DHDPS is a homotetramer
and each subunit with 300 amino acid residues
comprises: N-terminal (b/a)8-barrel domain (residues
1-233) and a C-terminal domain (residues 234-300),
which consists of three a-helices. The residues bounded
the active site are THR54, THR55 TYR143, ARG148 and
LYS171. Particularly, LYS171 responsible for substrate
binding and catalysis are located at the centre of each
monomer in the (b/a)8-barrel domain facing the central
cavity of the tetramer. In E. coli DHDPS enzyme the
equivalent residue is LYS161. Using PYMOL software, all
the 1587 water molecules, eight DTT molecules, eight
Mg
2+ and eight Cl
- ions were removed.
Docking of pyruvate analogues
First, 4088 drug-like pyruvate analogues were docked
into the active site of Mtb DHDPS. For the validation of
docking process, the substrate pyruvate was also intro-
duced as a control with the purpose of screening the
compounds with docking score greater than the sub-
strate. The detailed view of docking of pyruvate to the
active site is shown in Figure 2, which exhibited
molecular docking with ΔG value of -6.31 (kcal/mol).
The pyruvate lying near the vicinity of LYS171 observed
to be forming a hydrogen bond with side chain of
LYS171-NH2. Additionally, we also introduced 5 experi-
mentally known inhibitors i.e. Piperidine-2,6-dicar-
boxylic acid (43%), Dimethylpiperidine-2,6-
dicarboxylate (24%), Pyridine-2,6-dicarboxylic acid
(75%), 1,4-dihydro-4-oxopyridine-2,6-dicarboxylic acid
(73%) and Dimethyl-1,4-dihydro-4-oxopyridine-2,6-
dicarboxylate (84%) of Mtb DHDPS, inhibiting the
enzyme activity in the range of 24-84% [25]. These
inhibitors were mainly the analogues of the product
DHDP. The docking ΔG values (i.e. -6.38, -4.98, -7.67,
-7.60, and -6.39 kcal/mol respectively) ranked four of
these inhibitors correctly with respect to their percent
inhibition (%) values. Additionally, it was found that
four inhibitors were docked with better ΔG values than
substrate, however only one inhibitor (Dimethylpiper-
idine-2,6-dicarboxylate) which caused poor 24% inhibi-
tion of the enzyme actvity exhibited poor docking in
comparison with substrate and other inhibitors. Another
inhibitor, Pyridine-2,6-dicarboxylic acid, which caused
75% inhibition in the enzyme activity provided ΔGv a l u e
of -7.67 (kcal/mol).
For pyruvate analogues, ΔG values in the range of -9.07
to -3.37 (kcal/mol) was obtained. Approximately 374
compounds were found to be docked with ΔG values
better than pyruvate. Importantly, top 10 hits exhibited
s t r o n gb i n d i n gb yy i e l d i n gf r e ee n e r g yb i n d i n gv a l u e s
superior than -8.43 (kcal/mol) (Table 1). Further, we
Figure 2
Docking of pyruvate to the active site of Mtb DHDPS.
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terms of their structures and ligand-receptor interactions.
The top ligands were found to be lying deep into the
binding cavity exhibiting all major interactions such as
hydrogen bonding, Van der Waals (VDW) and hydro-
phobic (shown in Figure 3A and 3B). Nevertheless,
hydrogen bonding with LYS171 as well as with other
conserved active site residues was found to be dominat-
ing. For instance, the predicted inhibitors formed
hydrogen bonds with LYS171-NH2, ARG148-NH2,
TYR143-OH, THR54-OH and THR55-OH. Here, we
have shown the docking poses of top 3 compounds (or
their conformers) i.e Pyruvate_16012, Pyruvate_14540
and Pyruvate_10444 (Figure 4), revealing the binding of
these compounds at the active site much better than
substrate and experimentally known inhibitors. Though,
the importance of ARG148 has not been elucidated in
Mtb DHDPS, however, the conserved equivalent residue
i.e. ARG138 from E. coli DHDPS has been demonstrated
to be playing imperative role in binding, specifically feed
back inhibition for (S) - l y s i n e .H e n c e ,t h ep r e s e n t
observation i.e. involvement of ARG148 in binding
with few potential inhibitors could be further exploited
experimentally. The structures of top 10 compounds
docked with highly favorable scores i.e. more negative
values than substrate receptor complex are also given in
Table S1 (see Additional file 1). Most of these hits hold
the chemical structure feature group such as oxime,
sulfone, carboxylate, carbonic, carboxyl, nitroso, and
nitro. Furthermore, we have also calculated the correla-
tion between molecular weight and ΔG values for these
top hits. However, very low correlation value of -0.28
was obtained which indicated that the predicted binding
affinity was mainly due to specificty and not due to
molecular size.
Docking of pyruvate-like molecules
The virtual screening using 3D similarity based search
could provide two main advantages- i) helps to narrow
down the size of large databases/libraries to be screened,
which eventually reduces the computational time
required to dock each library compound and ii) 3D
searching retrieves the compounds, out of which some
are the same class of compounds to which query
Table 1: Top 10 pyruvate analogues with better free binding
energy values in comparison with substrate
S.No Inhibitors ΔG values (kcal/mol) Molecular Weight
1. Pyruvate_16012 -9.07 197.516
2. Pyruvate_14540 -8.94 192.133
3. Pyruvate_10444 -8.87 175.082
4. Pyruvate_14988 -8.81 194.129
5. Pyruvate_13516 -8.62 192.049
6. Pyruvate_10892 -8.60 177.078
7. Pyruvate_12332 -8.56 180.073
8. Pyruvate_14380 -8.54 193.141
9. Pyruvate_13658 -8.50 207.084
10. Pyruvate_11915 -8.43 162.063
Figure 3
Docking of pyruvate analogues. Pyruvate analogue lying deep into the binding pocket (A) of Mtb DHDPS by establishing
bonded and non-bonded interactions (B).
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compounds, which may directly lead to the discovery of
novel lead compounds.
The docking of 291 and 2349 pyruvate-like compounds
(structurally similar to pyruvate) retrieved from NCI and
PubChem was carried out using the same docking
protocol as mentioned earlier for pyruvate analogues.
For NCI library, 50 pyruvate-like compounds provided
free energy binding values better than pyruvate control,
wheras 8.9% of the compounds were not able to fit
perfectly into the binding pocket, yielding positive free
energy binding values. The ΔGv a l u e si nt h er a n g eo f-
9.03 to -8.16 (kcal/mol) and ids of the top 10 NCI
compounds are summarized in the Table 2. The
structures of these hits are given in Table S2 (see
Additional file 1). All these top hits were characterized
by aromaticity along with presence of heteratoms i.e., N,
Cl, Br in few compounds. These detailed analysis
revealed that these 10 inhibitors fit very well into the
binding pocket by establishing bonded and nonbonded
interactions with active site residue as shown in Figure 5.
Similar to the docking of pyruvate analogues, hydrogen
bonding was found to be dominant interactions with
LYS171, TYR143, THR54 and THR55. Furthermore, the
correlation between molecular weight and ΔG values for
these 10 inhibitors yielded lower value of -0.55.
The docking ΔG values for top 5 pyruvate-like compounds
of PubChem are listed in Table 3. Out of 2349, only 250
compounds exhibited docking with free binding energy
values better than the substrate. The tops hits were mainly
aromatic, however only one compound (PUB20975287)
was found to be aliphatic, which displayed strong binding
by yielding ΔG value of -8.40 (kcal/mol). The interactions
of these inhibitors with active site residue were mainly
through hydrogen bonding, VDW and hydrophobic as
shown in Figure 6 for the best docked compound i.e.
PUB20975287. The structures of these top 5 hits are given
in Table S3 (see Additional file 1)
Docking of anti-infectives
Besides, docking of very diverse 1750 anti-infectives
structures was also carried out. Interestingly, 28.5% of
the compounds provided positive ΔG values, revealing
their inadequacy in adjusting into the binding pocket
comfortably. Most of the remaining compounds though
provided negative ΔG values, however lower than the
substrate, hence, did not fit well in DHDPS binding
pocket. Very few 25 anti-infectives provided ΔG values
better than substrate and experimentally known inhibi-
tors. Interestingly, the top 2 anti-infectives though
provided -29 and -23 kcal/mol of ΔG values; however
these failed to establish any interactions with LYS171.
Table 4 and Table S4 (Additional file 1) show the free
energy binding values and structures for the next top 5
compounds respectively. The first two compounds with
ΔG values -12.3 and -10.2 (kcal/mol) were assumed to
be the best and potent inhibitors of DHDPS screened
out in the present study. The top PUB475318 was able
Figure 4
Binding poses for top three pyruvate analogues.
Table 2: Free binding energy values and structures for top ten
NCI hits
S.No Inhibitors ΔG values (kcal/mol) Molecular Weight
1. NSC 11535 -9.03 291.08
2. NSC 286493 -8.78 256.24
3. NSC 5598 -8.76 212.19
4. NSC 115134 -8.61 226.21
5. NSC 105301 -8.53 246.63
6. NSC 62754 -8.43 245.06
7. NSC 62757 -8.35 166.14
8. NSC 157880 -8.32 224.20
9. NSC 62753 -8.16 206.20
10. NSC 139986 -8.16 246.63
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establishing bonded and non-bonded interactions very
well as shown in Figure 7. The anti-infective PUB475318
is known by the name Cefmetazole, a semisynthetic
cephamycin antibiotic with a broad spectrum of activity
against both gram-positive and gram-negative micro-
organisms [31]. The compound was also explored
during the high throughput screening for the identifica-
tion of inhibitors against Mtb H37Rv [32]. On the other
hand, PUB455194, which was ranked second during
the screening process, is known as antiviral agent
inhibiting virion. We have also shown in Figure 8, the
docking poses of these top 2 anti-infectives establish-
ing hydrogen bonding at the active site of DHDPS.
Hence, docking of anti-infectives helped us in the
identification of compounds with more diverse topology
in comparison to pyruvate analogues or pyruvate-like
molecules.
Figure 5
Docking of pyruvate-like NCI compounds. Top predicted inhibitors from NCI databases establishing interactions with
active site residues of Mtb DHDPS.
Table 4: Docking results for top five anti-infectives retrieved
from PubChem database
S.No Inhibitors ΔG values (kcal/mol) Molecular Weight
1. PUB475318 -12.34 470.54
2. PUB455194 -10.21 351.23
3. PUB4451056 -8.58 139.028
4. PUB3092 -8.31 227.18
5. PUB702695 -8.29 184.13
Figure 6
Docking of pyruvate-like PubChem compound. Interactions established by the best docked PubChem compound
(PUB 20975287).
Table 3: Free binding energy values and structures for top five
PubChem compounds
S.No Inhibitors ΔG values (kcal/mol) Molecular Weight
1. PUB 20975287 -8.40 190.11
2. PUB19751056 -8.36 197.15
3. PUB240601 -8.27 197.15
4. PUB15288093 -7.91 179.14
5. PUB18799166 -7.90 179.14
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To conclude, we have employed several virtual screening
protocols such as generation of combinatorial library, 3D
flexible search and molecular docking to identify potential
inhibitors against Mtb DHDPS. Several potential drug-like
inhibitors have been screened out showing strong binding
affinity to Mtb DHDPS. Additionally, few anti-infectives
with highly diverse topology from the pyruvate also
displayed strong binding. Though experimental studies are
indispensable to mark them as lead compound for the
development of novel drugs against Mtb, however, screened
out inhibitors would undoubtedly aid the experimental
designing of antitubercular agents expeditiously.
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